-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/FcLyYTInOx
-
-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/yCkJhbOfED
-
-
Mashup Score: 1
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/hGydRmi5eJ
-
-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/GPWs4za9qG
-
-
Mashup Score: 1
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/2wkJKq3D6P
-
-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/XZPordyYAD
-
-
Mashup Score: 1
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/UCn5fA0Wsl
-
-
Mashup Score: 0
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/tS0IqUxXpR
-
-
Mashup Score: 1
Oral and Poster Abstracts 731. Clinical Autologous Transplantation: Results: Poster I Adult, Non-Biological, Therapies, Study Population, Clinically relevant Amrita Krishnan, MD1, Antje Hoering, PhD2, Parameswaran Hari, MBBS, MD3, Rachael Sexton, PhD2* and Robert Z. Orlowski, MD, PhD41City of Hope Medical Center, Duarte, CA2SWOG Statistical Center, Seattle,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/wesjrKbDcb
-
. @SWOG S1803 Ph3 Len +/- Daratumumab/rhuph20 as Post-ASCT Maintenance in Myeloma Using Minimal Residual Disease (#mmMRD) to direct Therapy Duration (DRAMMATIC) - @DoctorAKrishnan Hoering, @Phari Sexton, @Myeloma_Doc #ASH20 Abst 1515 https://t.co/IeLcOehWrr #NCT04071457 #mmsm https://t.co/f8rMhhDR9A